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Genetic polymorphismAbstract Background: There are many studies about the association of b fibrinogen gene G-455A
polymorphism and the risk of coronary heart disease (CHD). However, the results of these studies
are inconsistent.
Objective: This study aimed to investigate the association of b fibrinogen gene G-455A polymor-
phism with the risk of CHD using meta analysis. This study was limited to the Asian population.
Methods: Published studies from PubMed, Embase, and CNKI databases (up to December
20th, 2015) were searched for eligible publications. The following information was extracted from
each study: (1) name of first author; (2) year of publication; (3) country of origin; (4) sample size of
cases and controls, and (5) size of each allele. The combined odds ratios (ORs) and 95% confidence
intervals (95% CIs) for the association between b fibrinogen gene G-455A polymorphism and the
risk of CHD were assessed using random or fixed effect model. A comprehensive meta analysis
(CMA) 2.0 was used to analyze the data.
Results: Nineteen studies (4011 cases/3673 controls) regarding the association of b fibrinogen
gene G-455A polymorphism and the risk of CHD were included in this meta analysis. The results
indicated that b fibrinogen gene G-455A polymorphism was associated with increased (A vs. G: OR
95% CI = 1.42 [1.19–1.70], p< 0.001; AA vs. GG +GA: OR 95% CI = 1.60 [1.13–2.26],
p= 0.008; GA vs. GG+ AA: OR 95% CI = 1.30 [1.07–1.58], p= 0.008) and decreased the risk
of CHD (G vs. A: OR 95% CI = 0.70 [0.59–0.84], p< 0.001; GG vs. GA + AA: OR 95%
CI = 0.68 [0.55–0.84], p< 0.001).
Conclusions: In the Asian population, the b fibrinogen gene G-455A polymorphism was associ-
ated with the risk of CHD.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).donesia.
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Coronary heart disease (CHD), one of the main killers threat-
ening human health [1], a common cause of death worldwide
[2], resulting from atherosclerosis and thrombosis or
atherothrombosis [3], is a degenerative and inflammatory pro-
cess that begins within the blood vessel wall, causing it to
weaken, enlarge, and eventually impair blood flow through
the damaged artery [4]. CHD is the leading cause of death
worldwide and has become a true pandemic without borders.
World Health Organization (WHO) reported that 3.8 million
men and 3.4 million women worldwide died each year caused
by CHD, and more than 60% of the global burden of CHD
occurred in developing countries [5]. WHO [6] estimated that
17.5 million people died due to cardiovascular disease (CVD)
in 2012, representing 31% of all global deaths. Of these deaths,
about 7.4 million died due to CHD. The crude mortality rate
for CHD in Asia was 39.0 per 100,000 for men and 19.8 per
100,000 for women in 2011. Of these, Kazakhstan had the
highest and Japan had the lowest mortality rate [7].
CHD risk factors are classified into traditional risk factors
(modifiable i.e.: hypertension, diabetes, hyperlipidemia, obe-
sity, tobacco use, and physical inactivity; and non-modifiable
i.e.: age more than 45 years for men and more than 55 years
for women, gender, family history of premature CHD) and
selected emerging risk factors i.e.: C-reactive protein, small
LDL particles, lipoprotein(a), homocysteine, lipoprotein-
associated phospholipase A2, coagulation and hemostatic fac-
tors, apolipoproteins A and B, and white blood cell count [8].
Coagulation and hemostatic factors play an important role in
the pathogenesis of CHD. Folsom et al. [9] studied regarding
the association of hemostatic factors and the incidence of
CHD. They found that elevated levels of fibrinogen were the
risk factors and may play causative roles in CHD. SalomaaPlease cite this article in press as: Fajar JK, The b fibrinogen gene G-455A polymorph
Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.06.002et al. [10] studied about the association of hemostatic factors
and the risk of CHD in Finland. They showed an increase in
the accumulation of fibrinogen on the subject with CHD.
Zhang et al. [11] studied about fibrinogen level in Chinese pop-
ulation with CHD. They found that the higher fibrinogen
levels were independently linked with the presence and severity
of CHD.
Fibrinogen is a coagulation or inflammatory biomarker
strongly associated with atherogenesis [11]. Fibrinogen is an
abundant plasma protein, highly susceptible to such oxidative
modifications, and is therefore a potential marker for oxidative
protein damage [12]. Fibrinogen, coagulation factor I, is
synthesized in the liver and the plasma concentration is
1–4.0 g/L [13]. Fibrinogen consists of three pairs of polypep-
tide chains (Aa/Bb/c) which are encoded by different genes
located at q23–q32 of chromosome 4 [14]. Fibrinogen plays
an essential role in the hemostatic system to cause atheroscle-
rosis and thrombosis by bridging activated platelets and being
the key substrate for thrombin to establish a consolidating fib-
rin network [13]. The b fibrinogen gene has been reported to
confer susceptibility to thromboembolic diseases and increased
plasma fibrinogen levels, and high fibrinogen levels were
considered a common risk factor that exists in CHD [15].
Tybjaerg-Hansen et al. [16] showed that the A allele of the b
fibrinogen G-455A gene single nucleotide polymorphism
(SNP) (rs1800790) was reported to be associated with high
plasma fibrinogen levels. Therefore, b fibrinogen gene
G-455A polymorphism has an association with the pathogen-
esis of CHD through increasing levels of fibrinogen.
Several polymorphism studies investigated the association
of b fibrinogen gene G-455A polymorphism with the risk of
CHD, but they showed inconsistent results. Studies conducted
by Ma and Chen [17], Gong et al. [18], Liu et al. [19], Ma et al.
[20], Sun et al. [21], Wang et al. [22], Sun et al. [23], Wu et al.ism in Asian subjects with coronary heart disease: A meta analysis, Egypt J Med
The association of b-fibrinogen gene G-455A polymorphism with the risk of CHD 3[24], Li [25], and Lu et al. [26] showed that b fibrinogen gene
G-455A polymorphism was associated with an increased risk
of CHD, whereas, studies conducted by Lam et al. [27], Ma
and Chen [28], Lee et al. [29], Jin et al. [30], Yamada et al.
[31], Pegoraro et al. [32], Wang et al. [33], Sun et al. [34],
and Onrat et al. [35] showed that b fibrinogen gene G-455A
polymorphism had no significant association with an increased
risk of CHD. Meta analysis study is the solution to determine
the actual association of those several studies. Several meta
analysis studies, i.e.: Smith et al. [36] in World populations,
Gu et al. [2] in Chinese population, and Sabater-Lleal et al.
[37] in European, African, and American population have
reported the associations of b fibrinogen gene G-455A poly-
morphism with the risk of CHD, but no meta-analysis study
was reported in Asian population. However, most Asian coun-
tries have higher mortality from CHD compared with western
countries [7]. Therefore, meta analysis study on the association
of b fibrinogen gene G-455A polymorphism with the risk of
CHD in Asian population was necessary to do.
This study aimed to investigate the association of b fibrino-
gen gene G-455A polymorphism with the risk of CHD using
meta analysis in Asian population. The results of this study
are expected to be useful for the future treatment and preven-
tion of CHD. Besides, the results of this study are also
expected to be useful as the comparison to other studies
regarding the b fibrinogen gene G-455A polymorphism and
the risk of CHD.2. Materials and methods
2.1. Study designs
A meta-analysis was conducted to assess the association of b
fibrinogen gene G-455A polymorphism with the risk of CHD
in Asian population. To achieve this goal, several studies
regarding the b fibrinogen gene G-455A polymorphism with
the risk of CHD were collected for calculating combined
ORs 95% CI and assessed using fixed or random effect model.
Articles were searched in Pubmed, Embase, and China
National Knowledge Infrastructure (CNKI). The study was
conducted in October 2015–February 2016.
2.2. Study procedures
The procedures of this study were (1) identify the potentially
relevant studies through Pubmed, Embase, and CNKI up to
December 20th, 2015; (2) determine eligibility of the study,
the exclusion was done by several steps, i.e.: (a) by reading
the title and abstract, (b) study designs must comply with the
inclusion criteria, and (c) provide sufficient data to calculate
OR 95% CI; (3) collect abstract and full text data from the
studies; (4) collect the data for calculating OR 95% CI; and
(5) analyze data statistically.
2.3. Eligibility criteria and data extraction
Eligibility criteria consisted of predefined inclusion and exclu-
sion criteria. Studies were included in the analysis if they met
the following inclusion criteria: (1) case–control; (2) cohort;Please cite this article in press as: Fajar JK, The b fibrinogen gene G-455A polymorph
Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.06.002(3) cross-sectional studies; (4) randomized-controlled trials
(RCTs); (5) controlled before-and-after studies; (6) cross-over
studies; (7) evaluating the associations of b fibrinogen gene
G-455A polymorphism with the risk of CHD in Asian
countries (Afghanistan, Armenia, Azerbaijan, Bahrain,
Bangladesh, Bhutan, Brunei, Cambodia, China, Cyprus,
Georgia, India, Indonesia, Iran, Iraq, Israel, Japan, Jordan,
Kazakhstan, Kuwait, Kyrgyzstan, Laos, Lebanon, Malaysia,
Maldives, Mongolia, Myanmar, Nepal, North Korea, Oman,
Pakistan, Palestine, Philippines, Qatar, Russia, Saudi Arabia,
Singapore, South Korea, Sri Lanka, Syria, Taiwan, Tajikistan,
Thailand, Timor-Leste, Turkey, Turkmenistan, United Arab
Emirates, Uzbekistan, Vietnam, and Yemen); and (8) provid-
ing sufficient data for calculation of OR 95% CI. Some of
the required data were extracted from each study for calculat-
ing OR 95% CI. The following information was extracted
from each study: (1) name of first author; (2) year of publica-
tion; (3) country of origin; (4) sample size of cases and con-
trols, (5) size of each allele.
2.4. Search strategy and literature
PubMed, Embase, and CNKI were searched with no language
restrictions, using specified search terms to identify studies
published up to December 20th, 2015. The search strategy
involved the use of combination of the following key words:
(b fibrinogen G-455A) and (variant or variation or polymor-
phism) and (coronary disease or coronary heart disease or
coronary artery disease or myocardial infarct or ischemic heart
disease or CHD or IHD or MI or cardiovascular disease or
heart disease OR angina) in (Asian countries or Afghanistan,
Armenia, Azerbaijan, Bahrain, Bangladesh, Bhutan, Brunei,
Cambodia, China, Cyprus, Georgia, India, Indonesia, Iran,
Iraq, Israel, Japan, Jordan, Kazakhstan, Kuwait, Kyrgyzstan,
Laos, Lebanon, Malaysia, Maldives, Mongolia, Myanmar,
Nepal, North Korea, Oman, Pakistan, Palestine, Philippines,
Qatar, Russia, Saudi Arabia, Singapore, South Korea, Sri
Lanka, Syria, Taiwan, Tajikistan, Thailand, Timor-Leste, Tur-
key, Turkmenistan, United Arab Emirates, Uzbekistan, Viet-
nam, and Yemen). The publication languages were restricted
to English. The reference lists of retrieved articles were hand-
searched. If more than one article was published using the
same study data, only the study with the largest sample size
was included.2.5. Study variables
2.5.1. b fibrinogen G-455A
Fibrinogen is a coagulation or inflammatory biomarker
strongly associated with atherogenesis [11]. The measurement
results of this variable were G and A allele. Data were
obtained by the searching strategy. Nominal scale was used
to assess this variable.
2.5.2. Risk of CHD
CHD is a degenerative and inflammatory process that begins
within the blood vessel wall, causing it to weaken, enlarge,
and eventually impair blood flow through the damaged artery
[4]. The measurement results of this variable increased or
decreased the risk of CHD. The data were obtained by theism in Asian subjects with coronary heart disease: A meta analysis, Egypt J Med
Figure 1 Selection of articles for inclusion in meta-analysis.
Table 1 Characteristics of studies included in the meta-analysis.
Author and year Country End point Source of controls Sample size Number of
samples
CHD genotype Control
genotype
CHD Control GG GA AA GG GA AA
Ma and Chen (1999) [17] China CHD HB S 66 53 36 26 4 41 11 1
Lam et al. (1999) [27] Hongkong CAD HB S 55 209 33 13 9 111 87 11
Ma and Chen (2000) [28] China CHD PB S 94 68 58 32 4 51 16 1
Lee et al. (2001) [29] Korea CAD PB L 305 215 204 90 11 148 63 4
Gong et al. (2002) [18] China CHD HB S 148 173 74 66 8 112 54 7
Jin et al. (2002) [30] China CAD PB S 224 164 130 85 9 94 64 6
Liu et al. (2002) [19] China MI HB S 44 273 24 15 5 182 81 10
Ma et al. (2002) [20] China MI HB S 172 43 90 77 5 37 5 1
Yamada et al. (2002) [31] Japan MI HB L 445 464 346 96 3 353 104 7
Sun et al. (2004) [21] China CHD PB S 124 148 77 35 12 107 37 4
Pegoraro et al. (2005) [32] India MI PB L 195 300 150 43 2 243 57 0
Wang et al. (2005) [22] China MI HB S 40 40 21 17 2 32 7 1
Sun et al. (2007) [23] China CHD HB S 121 130 48 63 10 72 50 8
Wang et al. (2007) [33] China CAD PB S 90 115 48 34 8 74 33 8
Wu et al. (2007) [24] China CHD HB L 226 182 106 89 31 124 45 13
Li (2008) [25] China CHD HB S 86 78 44 31 11 58 18 2
Lu et al. (2008) [26] China MI PB L 508 503 358 144 6 325 162 16
Sun et al. (2009) [34] China CHD PB L 1019 466 613 372 34 297 151 18
Onrat et al. (2012) [35] Turkey MI PB S 49 49 27 15 7 25 20 4
Notes: PB, Population-based; HB, Hospital-based; CHD, coronary heart disease; CAD, coronary artery disease; MI, myocardial infarction;
S = small (<400); L = large (P400).
4 J.K. Fajarsearching strategy. Nominal scale was used to assess this
variable.
2.6. Statistical analysis
The correlation of b fibrinogen gene G-455A polymorphisms
with risk of CHD was estimated by calculating pooled ORs
and 95% CI. The significance of pooled ORs was determinedPlease cite this article in press as: Fajar JK, The b fibrinogen gene G-455A polymorph
Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.06.002by Z tests (p< 0.05 was considered statistically significant).
A Q test was performed to evaluate whether the heterogeneity
existed. Random effect model was used to calculate OR 95%
CI if heterogeneity existed (p< 0.10). Fixed effect model
was used to calculate OR 95% CI if no heterogeneity existed.
Publication bias was assessed using Egger’s test (p< 0.05 was
considered statistically significant). Subgroup analyses based
on cardiovascular end point (CHD= coronary heart disease,ism in Asian subjects with coronary heart disease: A meta analysis, Egypt J Med
Figure 2 Meta-analysis of the association between b fibrinogen G-455A polymorphisms and CHD risk (A vs. G).
Figure 3 Meta-analysis of the association between b fibrinogen G-455A polymorphisms and CHD risk (GA vs. GG+ AA).
The association of b-fibrinogen gene G-455A polymorphism with the risk of CHD 5CAD= coronary artery disease, MI = myocardial infarc-
tion), source of controls (PB = population-based, HB = hos-
pital-based), and sample size (small <400, large P400
samples) were also performed. A comprehensive meta analysis
(CMA) 2.0 was used to analyze the data.
3. Results
3.1. Characteristics of the studies
A total of 2066 potentially relevant papers were identified
based on the search strategy. Of these, 2036 papers were
excluded because of obvious irrelevance by reading their titles
and abstracts. After the full texts were read, three papers were
excluded because they did not provide sufficient data for calcu-
lation of OR with 95% CI; another paper was excluded
because it was a family-based study. In addition, five reviewsPlease cite this article in press as: Fajar JK, The b fibrinogen gene G-455A polymorph
Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.06.002and two comments were excluded. A flow chart demonstrating
the inclusion or exclusion of studies is displayed as Fig. 1. A
total of 19 studies were included in the meta analysis. Hon-
gkong, Korea, Japan, India, and Turkey each had only one
study, while 14 other studies were from China. Table 1
described the characteristics of the studies included in the meta
analysis.
3.2. Quantitative data synthesis
A total of 4011 cases and 3673 controls were identified. Over-
all, the results showed significant association between b fib-
rinogen gene G-455A polymorphism with the risk of CHD.
The results indicated that b fibrinogen gene G-455A polymor-
phisms were associated with increased (A vs. G: OR 95%
CI = 1.42 [1.19–1.70], p< 0.001; AA vs. GG+ GA: OR
95% CI = 1.60 [1.13–2.26], p= 0.008; GA vs. GG+ AA:ism in Asian subjects with coronary heart disease: A meta analysis, Egypt J Med
Table 2 Summary ORs and 95% CIs of the association between b fibrinogen G-455A polymorphism and CHD risk.
No. Alleles Parameter All End point Source of controls Sample size
CHD CAD MI HB PB S L
1 A vs. G OR 1.42 1.71 1.12 1.34 1.76 0.15 1.62 1.13
95% CI 1.19–1.70 1.34–2.18 0.93–1.36 0.93–1.93 1.33–2.33 0.96–1.38 1.34–1.97 0.87–1.47
P <0.001 <0.001 0.217 0.116 <0.001 0.131 <0.001 0.369
PH <0.001 0.004 0.666 <0.001 <0.001 0.016 0.025 <0.001
PE 0.319 0.274 <0.001 0.413 0.367 0.201 0.243 0.296
2 AA vs. GG+GA OR 1.60 1.57 1.84 1.23 1.99 1.31 2.08 1.02
95% CI 1.13–2.26 1.12–2.21 1.09–3.08 0.52–2.91 1.39–2.87 0.78–2.19 1.47–2.94 0.52–2.01
P 0.008 0.009 0.021 0.639 <0.001 0.303 <0.001 0.945
PH 0.043 0.158 0.362 0.039 0.337 0.070 0.732 0.020
PE 0.453 0.370 0.137 0.822 0.217 0.501 <0.001 0.626
3 GA vs. GG+ AA OR 1.30 1.47 0.92 1.27 1.65 1.06 1.47 1.12
95% CI 1.07–1.58 1.26–1.72 0.62–1.37 0.86–1.87 1.14–2.38 0.94–1.21 1.08–1.98 0.90–1.39
P 0.008 <0.001 0.703 0.224 0.008 0.343 0.014 0.316
PH <0.001 0.278 0.056 <0.001 <0.001 0.310 <0.001 0.024
PE 0.327 0.117 0.310 0.417 0.493 0.086 0.440 0.209
4 G vs. A OR 0.70 0.58 0.88 0.75 0.57 0.87 0.62 0.89
95% CI 0.59–0.84 0.54–0.74 0.73–1.07 0.52–1.07 0.43–0.75 0.72–1.04 0.51–0.75 0.68–1.16
P <0.001 <0.001 0.217 0.116 <0.001 0.131 <0.001 0.369
PH <0.001 0.004 0.666 <0.001 <0.001 0.016 0.025 <0.001
PE 0.319 0.274 <0.001 0.413 0.367 0.201 0.243 0.296
5 GG vs. GA+ AA OR 0.68 0.53 0.94 0.72 0.52 0.88 0.58 0.86
95% CI 0.55–0.84 0.41–0.70 0.74–1.18 0.48–1.09 0.36–0.74 0.73–1.07 0.45–0.76 0.65–1.15
P <0.001 <0.001 0.611 0.126 <0.001 0.196 <0.001 0.317
PH <0.001 0.017 0.342 <0.001 <0.001 0.069 0.003 <0.001
PE 0.376 0.281 0.081 0.468 0.494 0.182 0.371 0.314
Notes: OR, odds ratio; CI, confidence interval; P, P value based on Z test between-study; PH, P value based on Q test for between-study
heterogeneity; PE, P value based on Egger’s test between-study; PB, population-based; HB, hospital-based; CHD, coronary heart disease; CAD,
coronary artery disease; MI, myocardial infarction; S, small (<400); L, large (P400).
6 J.K. FajarOR 95% CI = 1.30 [1.07–1.58], p= 0.008) and decreased the
risk of CHD (G vs. A: OR 95% CI = 0.70 [0.59–0.84],
p< 0.001; GG vs. GA+ AA: OR 95% CI = 0.68 [0.55–
0.84], p< 0.001). Forest plot regarding the correlation of b
fibrinogen gene G-455A polymorphism with the risk of CHD
is described in Fig. 2 for A vs. G and Fig. 3 for the GA vs.
GG+ AA, while, summary ORs and 95% CIs regarding the
correlation of b fibrinogen gene G-455A polymorphism with
the risk of CHD is described in Table 2. In the subgroup anal-
ysis, the b fibrinogen gene G455A polymorphism was associ-
ated with the risk of CHD in all genetic model of CHD end
point subgroup (A vs. G p< 0.001; AA vs. GG+GA
p= 0.009; GA vs. GG+ AA p< 0.001; G vs. A p< 0.001;
GG vs. GA+ AA p< 0.001), one genetic model of CAD
end point subgroup (AA vs. GG+ GA p= 0.021), all genetic
model of HB source of control subgroup (A vs. G p< 0.001;
AA vs. GG+ GA p< 0.001; GA vs. GG+ AA p= 0.008; G
vs. A p< 0.001; GG vs. GA+ AA p< 0.001), and all genetic
model of small sample size subgroup (A vs. G p< 0.001; AA
vs. GG+ GA p< 0.001; GA vs. GG+ AA p= 0.014; G vs.
A p< 0.001; GG vs. GA+ AA p< 0.001), while, the b fib-
rinogen gene G455A polymorphism had no significant associ-
ation with the risk of CHD in four genetic models of CAD end
point subgroup (A vs. G p= 0.217; GA vs. GG+ AA
p= 0.703; G vs. A p= 0.217; GG vs. GA + AA
p= 0.611), all genetic model of MI end point subgroup (A
vs. G p= 0.116; AA vs. GG+ GA p= 0.639; GA vs. GG
+ AA p= 0.224; G vs. A p= 0.116; GG vs. GA + AA
p= 0.126), all genetic model of PB source of control subgroupPlease cite this article in press as: Fajar JK, The b fibrinogen gene G-455A polymorph
Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.06.002(A vs. G p= 0.131; AA vs. GG+ GA p= 0.303; GA vs. GG
+ AA p= 0.343; G vs. A p= 0.131; GG vs. GA + AA
p= 0.196), and all genetic model of large sample size sub-
group (A vs. G p= 0.369; AA vs. GG+GA p= 0.945;
GA vs. GG+ AA p= 0.316; G vs. A p= 0.369; GG vs.
GA+ AA p= 0.317).
3.3. Source of heterogeneity
Evidence for heterogeneity (p< 0.10) between studies was
found in all multiplication (A vs. G, p< 0.001; AA vs. GG
+GA, p= 0.043; GA vs. GG+ AA, p< 0.001; G vs. A,
p< 0.001; GG vs. GA + AA, p< 0.001). Therefore, the data
in this study were assessed using random effects model. Sum-
mary evidence of heterogeneity regarding the correlation of b
fibrinogen gene G-455A polymorphism with the risk of CHD
is described in Table 2. In the subgroup analysis, evidence
for heterogeneity was found in CHD end point subgroup (A
vs. G p= 0.004; G vs. A p= 0.004; GG vs. GA+ AA
p= 0.017), MI end point subgroup (A vs. G p< 0.001; AA
vs. GG+GA p= 0.039; GA vs. GG+ AA p< 0.001; G
vs. A p< 0.001; GG vs. GA + AA p< 0.001), HB source
of control subgroup (A vs. G p< 0.001; GA vs. GG+ AA
p< 0.001; G vs. A p< 0.001; GG vs. GA + AA
p< 0.001), PB source of control subgroup (A vs. G
p= 0.016; G vs. A p= 0.016), small sample size subgroup
(A vs. G p= 0.025; GA vs. GG+ AA p< 0.001; G vs. A
p= 0.025; GG vs. GA + AA p= 0.003), and large sample
size subgroup (A vs. G p< 0.001; AA vs. GG+ GAism in Asian subjects with coronary heart disease: A meta analysis, Egypt J Med
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GG vs. GA + AA p< 0.001). Therefore, random effects
model was used to calculate OR 95% CI in these subgroup,
while, no evidence for heterogeneity was found in CHD end
point subgroup (AA vs. GG+ GA p= 0.158; GA vs. GG
+ AA p= 0.278), CAD end point subgroup (A vs. G
p= 0.666; AA vs. GG+ GA p= 0.362; GA vs. GG+ AA
p= 0.056; G vs. A p= 0.666; GG vs. GA + AA
p= 0.342), HB source of control subgroup (AA vs. GG
+ GA p= 0.337), PB source of control subgroup (AA vs.
GG+GA p= 0.070; GA vs. GG+ AA p= 0.310; GG vs.
GA + AA p= 0.069), and small sample size subgroup (AA
vs. GG+ GA p= 0.732). Therefore, fixed effect model was
used to calculate OR 95% CI in these subgroup.
3.4. Potential publication bias
Using Egger’s test, no publication bias could be detected (A vs.
G, p= 0.319; AA vs. GG+GA, p= 0.453; GA vs. GG
+ AA, p= 0.327; G vs. A, p= 0.319; GG vs. GA+ AA,
p= 0.376). Summary Egger’s test regarding the correlation
of b fibrinogen gene G-455A polymorphism with the risk of
CHD is described in Table 2. In the subgroup analysis, no pub-
lication bias was detected in CHD end point subgroup (A vs.
G p= 0.274; AA vs. GG+GA p= 0.370; GA vs. GG
+ AA p= 0.117; G vs. A p= 0.274; GG vs. GA + AA
p= 0.281), CAD end point subgroup (AA vs. GG+GA
p= 0.137; GA vs. GG+ AA p= 0.310; GG vs. GA + AA
p= 0.081), MI end point subgroup (A vs. G p= 0.413; AA
vs. GG+ GA p= 0.822; GA vs. GG+ AA p= 0.417; G
vs. A p= 0.413; GG vs. GA+ AA p= 0.468), HB source
of control subgroup (A vs. G p= 0.367; AA vs. GG+GA
p= 0.217; GA vs. GG+ AA p= 0.493; G vs. A p= 0.367;
GG vs. GA+ AA p= 0.494), PB source of control subgroup
(A vs. G p= 0.201; AA vs. GG+ GA p= 0.501; GA vs. GG
+ AA p= 0.086; G vs. A p= 0.201; GG vs. GA + AA
p= 0.182), small sample size subgroup (A vs. G p= 0.243;
GA vs. GG+ AA p= 0.440; G vs. A p= 0.243; GG vs.
GA + AA p= 0.371), and large sample size subgroup (A vs.
G p= 0.296; AA vs. GG+GA p= 0.626; GA vs. GG
+ AA p= 0.209; G vs. A p= 0.296; GG vs. GA + AA
p= 0.314), while, publication bias was detected in CAD end
point subgroup (A vs. G p< 0.001; G vs. A p< 0.001) and
small sample size subgroup (AA vs. GG+ GA p< 0.001).
4. Discussion
Fibrinogen is a coagulation or inflammatory biomarker
strongly associated with atherogenesis [11]. Fibrinogen plays
an essential role in the hemostatic system by bridging activated
platelets and being the key substrate for thrombin to establish
a consolidating fibrin network [13]. Several prospective and
cross-sectional studies have revealed that plasma fibrinogen
levels had a strong predictive value for CHD. Folsom et al.
[9] studied about the association of fibrinogen levels and the
incidence of CHD. They found that elevated levels of fibrino-
gen were risk factors and may play causative roles in CHD.
Salomaa et al. [10] studied about the association of fibrinogen
and the risk of CHD in Finland. They showed that an elevated
level of fibrinogen was associated with the risk of CHD. Zhang
et al. [11] studied about the association of fibrinogen level withPlease cite this article in press as: Fajar JK, The b fibrinogen gene G-455A polymorph
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higher fibrinogen level was independently linked with the pres-
ence and severity of CHD. Eriksson et al. [38] studied about
the association of plasma fibrinogen with the risk of CHD.
They found that plasma fibrinogen was associated with an
excess risk of CHD. Because of the effects of fibrinogen on
inflammatory response, a series of studies have focused on
the contribution of polymorphisms within fibrinogen cluster
genes to the risk of CHD. However, results have been contra-
dictory. This study reported the association of b fibrinogen
gene G-455A polymorphism with the risk of CHD, although
there were still the limited power of meta analysis due to size
and heterogeneity of studies.
This results suggested that b fibrinogen gene G-455A poly-
morphism was associated with increased (A vs. G: OR 95%
CI = 1.42 [1.19–1.70], p< 0.001; AA vs. GG+ GA: OR
95% CI = 1.60 [1.13–2.26], p= 0.008; GA vs. GG+ AA:
OR 95% CI = 1.30 [1.07–1.58], p= 0.008) and decreased
the risk of CHD (G vs. A: OR 95% CI = 0.70 [0.59–0.84],
p< 0.001; GG vs. GA+ AA: OR 95% CI = 0.68 [0.55–
0.84], p< 0.001) in Asian population. Summary of ORs
95% CIs, correlation, heterogeneity, and Egger’s test regarding
the correlation of b fibrinogen gene G-455A polymorphism
with the risk of CHD is described in Table 2 while study char-
acteristics are described in Table 1. Forest plot regarding the
correlation of b fibrinogen gene G-455A polymorphism with
the risk of CHD is described in Fig. 2 for A vs. G and
Fig. 3 for the GA vs. GG+ AA. Previous meta-analysis stud-
ies have also reported the correlation of b fibrinogen gene G-
455A polymorphism with the risk of CHD in different popula-
tion. Smith et al. [36] studied about the association of b fib-
rinogen gene G-455A polymorphism with the risk of CHD
in World populations. They showed a significant association
between b fibrinogen gene G-455A polymorphism and the risk
of CHD (OR 95% CI = 0.976 [0.916–1.040]). Gu et al. [2]
studied about the association of b fibrinogen gene G-455A
polymorphism with the development of CHD in Chinese pop-
ulation. They found that b fibrinogen gene G-455A polymor-
phism was associated with the development of CHD (OR
95% CI = 1.802 [1.445–2.246]). Sabater-Lleal et al. [37] stud-
ied about the correlation of 23 fibrinogen genes including b fib-
rinogen G-455A and the risk of CHD in European, African,
and American population. They found all 23 fibrinogen-
associated lead single nucleotide polymorphisms were not sig-
nificant for CHD. Chen et al. [39] conducted a study on the
correlation between the b fibrinogen gene -148C/T and -
455G/A polymorphisms with the risk of CHD in Chinese pop-
ulation. They found that b fibrinogen gene G-455A polymor-
phism (in particular, allele A) increased susceptibility to
CHD (OR 95% CI = 1.75 [1.24–2.46]). Li et al. [1] conducted
a meta analysis study regarding the relationship between APO
A5 -1131T/C, b fibrinogen G-455A, -148C/T, and CETP
TaqIB gene polymorphisms with the risk of CHD in Chinese
population. They found a significant association between b fib-
rinogen G-455A gene polymorphism with CHD susceptibility
(OR 95% CI = 1.50 [1.25–1.81]). The results of this study
had similarities with several meta-analysis studies regarding
b fibrinogen gene G-455A polymorphism related to the risk
of CHD, except a study by Sabater-Lleal et al. [37]. This differ-
ence was unexplainable. However, the possibilities were
because of too many genes observed by Sabater-Lleal et al.
[37]. Therefore, it would affect the final results. In addition,ism in Asian subjects with coronary heart disease: A meta analysis, Egypt J Med
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was provided. Therefore, the association was immeasurable.
Furthermore, in the subgroup analysis, the b fibrinogen gene
G455A polymorphism was associated with the risk of CHD
in all genetic model of CHD end point subgroup, one genetic
model of CAD end point subgroup (AA vs. GG+ GA), all
genetic model of HB source of control subgroup, and all
genetic model of small sample size subgroup, while, the b fib-
rinogen gene G455A polymorphism had no significant associ-
ation with the risk of CHD in four genetic models of CAD end
point subgroup (A vs. G; GA vs. GG+ AA; G vs. A; GG vs.
GA+ AA), all genetic model of MI end point subgroup, all
genetic model of PB source of control subgroup, and all
genetic model of large sample size subgroup. However, these
results should be interpreted with caution because the rela-
tively small sample size or multiple testing could drive false
positive findings.
These results also indicated that the A allele of b fibrinogen
gene G-455A was correlated with susceptibility to the risk of
CHD, while the G allele was correlated with reduced risk of
CHD. See Table 2 for detail about summary of ORs 95%
CIs regarding the correlation of b fibrinogen gene G-455A
polymorphism with the risk of CHD. Theoretically, these
results were unexplainable clearly. However, several studies
had supported these results. Theodoraki et al. [40] conducted
a study regarding the effect of fibrinogen A (FGA), fibrinogen
B (FGB), and fibrinogen G (FGG) genes SNPs and haplotypes
on susceptibility to CAD in a homogeneous Greek population.
They showed that rs1800789 or G allele of b fibrinogen G-
455A seem to confer protection to CHD. Rallidis et al. [41]
conducted a study regarding the association of b fibrinogen
gene G-455A with development of myocardial infarction. They
found that the presence of the G allele of b fibrinogen G-455A
had a protective effect against the development of non-fatal
myocardial infarction 635 years of age in Greek population.
Other studies showed that A allele of b fibrinogen G-455A
was associated with an increased risk of CHD. Smith et al.
[36] conducted a meta analysis regarding the relationship
between b fibrinogen G-455A with CHD risk in World popu-
lations. They showed a significant association between A allele
of b fibrinogen G-455A and an increased risk of CHD (OR
95% CI = 0.976 [0.916–1.040]). Chen et al. [39] conducted a
meta analysis regarding correlation of b fibrinogen gene -
148C/T and -455G/A polymorphisms and susceptibility to
CHD in Chinese population. They showed that A allele of b
fibrinogen G-455A increased susceptibility to CHD (OR
95% CI = 1.75 [1.24–2.46]). A study by Folsom et al. [42] ana-
lyzed regarding the relationship between b fibrinogen G-455A
with CHD risk. They found that plasma fibrinogen was higher
significantly in A allele of b fibrinogen G-455A. Papageorgiou
et al. [43] conducted a study on the effects of the G455A and
the G58A fibrinogen genetic polymorphisms on prothrombotic
profile, endothelial function and the risk of CHD in a Cau-
casian population. They found that A allele of b fibrinogen
G-455A was associated with increased fibrinogen levels,
although no significant effect was observed. Therefore, the
results of this study that showed A allele of b fibrinogen G-
455A correlated with the susceptibility of CHD was possible
because A allele of b fibrinogen G-455A had an association
with increased levels of plasma fibrinogen. In the previous dis-
cussion we explained that the increased level of plasma fibrino-
gen had a close correlation with the risk of CHD as reportedPlease cite this article in press as: Fajar JK, The b fibrinogen gene G-455A polymorph
Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.06.002by Folsom et al. [9], Salomaa et al. [10], Zhang et al. [11],
and Eriksson et al. [38].
Atherosclerosis plays an important role in the occurrence of
CHD [3]. The role of fibrinogen in the atherosclerosis process
is complex. The role of fibrinogen to cause atherosclerosis
includes: (1) fibrinogen is bound to platelet GpIIb/IIIa mem-
brane receptors and forms a web that provides stability to
the newly-formed thrombus, (2) fibrinogen promotes the adhe-
sion of platelets and white blood cells to the endothelial surface
[40], (3) fibrinogen is involved in the earliest stages of plaque
formation to encourage smooth muscle cell (SMC) migration
and proliferation, and contribute to the growth of plaques
[44], (4) fibrin influences accumulation of the lipid core in
fibrous plaques which appears to bind the lipoprotein Lp(a)
with high affinity, thereby immobilizing its lipid moiety within
the lesion [45], (5) fibrinogen regulates or controls the expres-
sion of P-selectin during the formation and or development of
atherosclerosis and thus facilitates atherosclerotic lesion devel-
opment and promotes plaque formation [46]. These mecha-
nisms are thought to underlie the results of this study that
showed a correlation between b fibrinogen gene G-455A poly-
morphism with the risk of CHD.
There were several limitations in the meta-analysis. First,
this analysis was primarily based on unadjusted effect esti-
mates. Therefore, the potential covariates including age, gen-
der, and environmental factors such as smoking and levels of
HDL cholesterol, which might influence the effect estimates,
were not controlled for. Second, the possibility of a false neg-
ative remains due to the small size of the studies even when
combined. Thus, further studies with a larger sample size are
required to investigate the associations. Third, this study could
not be generalized to the all Asian population because most
samples of this study were Chinese population, while the pop-
ulation of other Asian countries was very limited.
5. Conclusions and suggestions
In summary, this meta analyses suggested that b fibrinogen
gene G-455A polymorphism was associated with decreased
and increased the risk of CHD in Asian population. Further
studies considering gene–environment interactions should be
conducted to investigate the associations between b fibrinogen
gene G-455A polymorphisms and the risk of CHD. It is neces-
sary to study the correlation of b fibrinogen gene G-455A poly-
morphisms with the risk of CHD in Kazakhstan, a country
with the highest mortality rate of CHD in Asia, because none
of the studies reported the correlation of b fibrinogen gene G-
455A polymorphisms with the risk of CHD in Kazakhstan.
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